Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been given a consensus rating of “Hold” by the ...

Good news for new moms in Alabama: The state House has has approved a substitute bill (SUB HB322) that would require healthcare professionals to screen for postpartum depression (PPD) in mothers ...

CLEVELAND — According to the CDC, one in eight women suffer postpartum depression that can last weeks or sometimes months, and in some cases can be devastating. While there are drugs available ...

Biogen believes that some of its new drugs, Eisai-partnered Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia and Zurzuvae for depression, have the potential to revive long ...